diffuse large b-cell lymphoma Clinical Research Trials

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
New/Updated Trials

Male only (2)
Any (299)

Phase 1 (85)
Phase 2 (79)
Phase 3 (20)
Phase 4 (3)
Phase 1/2 (56)
Phase 2/3 (6)
Unknown (52)

Interventional (266)
Observational (31)

National Cancer Institute (NCI) (17)
Fred Hutchinson Cancer Research Center (7)
Ruijin Hospital (6)
Celgene (5)
M.D. Anderson Cancer Center (5)
Mayo Clinic (5)
Memorial Sloan Kettering Cancer Center (5)
Novartis Pharmaceuticals (5)
University of Washington (5)
City of Hope Medical Center (4)
Genmab (4)
Stichting Hemato-Oncologie voor Volwassenen Nederland (4)
Sun Yat-sen University (4)
The First Affiliated Hospital with Nanjing Medical University (4)
The Lymphoma Academic Research Organisation (4)
David Bond, MD (3)
Fondazione Italiana Linfomi ONLUS (3)
Henan Cancer Hospital (3)
Huiqiang Huang (3)
Icahn School of Medicine at Mount Sinai (3)
Juno Therapeutics, a Subsidiary of Celgene (3)
Masonic Cancer Center, University of Minnesota (3)
Second Affiliated Hospital, School of Medicine, Zhejiang University (3)
University of Chicago (3)
ADC Therapeutics S.A. (2)
Austin Health (2)
Barbara Ann Karmanos Cancer Institute (2)
BeiGene (2)
Calibr, a division of Scripps Research (2)
Duke University (2)
Fudan University (2)
Gilead Sciences (2)
H. Lee Moffitt Cancer Center and Research Institute (2)
Herlev Hospital (2)
Hospices Civils de Lyon (2)
Institute of Hematology & Blood Diseases Hospital (2)
Jonsson Comprehensive Cancer Center (2)
Lars Møller Pedersen (2)
MEI Pharma, Inc. (2)
Nordic Lymphoma Group (2)
Samsung Medical Center (2)
Seagen Inc. (2)
Shanghai Ming Ju Biotechnology Co., Ltd. (2)
TG Therapeutics, Inc. (2)
Takeda (2)
University Hospital Muenster (2)
University Hospital Southampton NHS Foundation Trust (2)
Wuhan University (2)
AIDS Malignancy Consortium (1)
AVM Biotechnology LLC (1)
Academic and Community Cancer Research United (1)
Acerta Pharma BV (1)
Adicet Bio, Inc (1)
Antengene Corporation (1)
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.) (1)
Arcus Biosciences, Inc. (1)
Asan Medical Center (1)
AstraZeneca (1)
Autolus Limited (1)
Bambino Gesù Hospital and Research Institute (1)
Baylor College of Medicine (1)
Beijing InnoCare Pharma Tech Co., Ltd. (1)
Beth Christian (1)
Bio-Path Holdings, Inc. (1)
Boehringer Ingelheim (1)
Boryung Pharmaceutical Co., Ltd (1)
C. Babis Andreadis (1)
Cambridge University Hospitals NHS Foundation Trust (1)
Case Comprehensive Cancer Center (1)
Catherine Bollard (1)
Celldex Therapeutics (1)
Cellectar Biosciences, Inc. (1)
Central Hospital, Nancy, France (1)
Centre Antoine Lacassagne (1)
Chipscreen Biosciences, Ltd. (1)
Chongqing Precision Biotech Co., Ltd (1)
Constellation Pharmaceuticals (1)
Crystal Mackall, MD (1)
Curis, Inc. (1)
Curocell Inc. (1)
Cyteir Therapeutics, Inc. (1)
CytomX Therapeutics (1)
Dana-Farber Cancer Institute (1)
Deepa Jagadeesh (1)
Dong-A University Hospital (1)
Eden BioCell Ltd. (1)
Epizyme, Inc. (1)
First Affiliated Hospital of Harbin Medical University (1)
First Affiliated Hospital of Zhejiang University (1)
Fox Chase Cancer Center (1)
French Innovative Leukemia Organisation (1)
Fujian Medical University (1)
Fundación Academia Española de Dermatología (1)
GWT-TUD GmbH (1)
German CLL Study Group (1)
Gruppo Italiano Malattie EMatologiche dell'Adulto (1)
Guangdong Provincial People's Hospital (1)
Hebei Senlang Biotechnology Inc., Ltd. (1)
Hrain Biotechnology Co., Ltd. (1)
Hutchison Medipharma Limited (1)

No (297)
Yes (4)

Updated trials (34)
New trials (6)

I am/have/had

I am/have/hadb-cell lymphoma

I am/have/hadmeasurable disease

I am/have/hadfollicular lymphoma

I am/have/hadhodgkin's disease

I am/have/hadcancer

I am/have/hadgilbert's syndrome

I am/have/hadcell transplantation

I am/have/hadmantle cell lymphoma

I am/have/hadneutrophil count

I am/have/hadhigh grade b-cell lymphoma

I am/have/hadchronic lymphocytic leukemia

I am/have/hadda-epoch

I am/have/hadsalvage therapy

I am/have/hadautograft

I am/have/hadindolent lymphoma

I am/have/hadmarginal zone lymphoma

I am/have/hadburkitt's lymphoma

I am/have/hadchemoimmunotherapy

I am/have/hadleukemia

I am/have/hadline of therapy

added new label for I am/have/had

I am looking for

I am looking forrituximab

I am looking forvincristine

I am looking forcyclophosphamide

I am looking fordoxorubicin

I am looking forprednisone

I am looking foranthracyclines

I am looking foretoposide

I am looking forvenetoclax

I am looking forbendamustine

I am looking forlenalidomide

I am looking foralkylating agent

I am looking formonoclonal antibodies

I am looking foranti-cd20 monoclonal antibody

I am looking forcytarabine

I am looking forconjugated bilirubin

I am looking forbtk inhibitor

I am looking forgemcitabine

I am looking forbrentuximab

I am looking fordexamethasone

I am looking foravid

added new label for I am looking for

Advanced Filters

Found 301 clinical trials

featured

TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US

(diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central nervous system

1875 views
26 Mar, 2021
15 locations

featured

TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US Spanish

268 views
26 Mar, 2021
16 locations

featured

Phase 1
For Seniors
For adults
For all genders
Hematology
Recruiting

A safety and Tolerability Study of INCB053915 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).

b-cell lymphoma

lymphomas

lymphoma

45 views
14 Dec, 2020
5 locations

featured

For pediatric ages
For adults
For all genders
Recruiting

A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

180 views
25 Mar, 2021
1 location

Multi-country trial
Phase 2
For adults
Recruiting in 100s
Interventional Study
For all genders
Recruiting

Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis

large B-cell lymphoma (DLBCL).

burkitt's lymphoma

large cell lymphoma

t-cell lymphoma

transformed lymphoma

follicular lymphoma

32 views
23 Jan, 2021
18 locations

Multi-country trial
Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
For all genders
Recruiting

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer.

This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participant ramp-up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory haematological malignancies.

0 views
13 Jun, 2021
24 locations

Phase 3
For adults
Recruiting in 100s
Interventional Study
For all genders
Recruiting

Thalidomide Maintenance Treatment in DLBCL

This is a randomized, multi-center,phase III study to evaluate the ability of thalidomide maintenance therapy to prolong relapse-free survival in diffuse large B cell lymphoma(DLBCL).

b-cell lymphoma

rituximab

15 views
21 Jan, 2021
1 location

Phase 2
For Seniors
For adults
Recruiting in 10s
Interventional Study
For all genders
Recruiting

Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma

with relapsed or refractory chemosensitive diffuse large B-cell lymphoma

high dose chemotherapy

lenalidomide

rituximab

b-cell lymphoma

cancer chemotherapy

28 views
07 Nov, 2020
1 location

Phase 2
For adults
Recruiting in 10s
Interventional Study
For all genders
Recruiting

GVD R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

rituximab) regimen for autologous hematopoietic stem cell transplantation(ASCT)-eligible patients with refractory/relapsed diffuse large B-cell lymphoma.

cell transplantation

rituximab

gemcitabine

b-cell lymphoma

doxorubicin

0 views
23 Jan, 2021
1 location

Phase 2
For Seniors
For adults
Recruiting in 10s
Interventional Study
For all genders
Recruiting

Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL

treatment of transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.

cell transplantation

rituximab

cancer

salvage therapy

anthracyclines

0 views
23 Jan, 2021
1 location